Migraine Clinical Trial
This study will be conducted as a retrospective study of exposed and unexposed cohort of the
French population included all beneficiaries aged 65 and older. Exposed patients will be
matched to non exposed controls according age, gender and area of residence (ratio 1/4). Two
exposed arms and two non exposed control arms will be planned. Triptan arm will be user of
triptan defined as at least one recorded dispensing of any drug during the follow up, with
no recorded of any of these drugs during the previous 6 months ("new or incident users").
Ergot arm will be user of ergot derivative defined as at least one recorded dispensing of
any drug during the follow up, with no recorded of any of these drugs during the previous 6
months ("new or incident users"). This study involved data from the French National Health
Insurance Information System (Système National d‟Information Inter-Régimes de l‟Assurance
Maladie ; SNIIRAM) linked with the French hospital discharge database (Programme de
Médicalisation des Systèmes d‟Informations, PMSI).
- The SNIIRAM is a vast national medico-administrative database representing the most
part of the French population, allowing to identify and to describe precisely all
medication dispensations (name of drug, date of dispensing and quantity) including
triptans and other reimbursed medications.
- The PMSI provides medical information about all patients admitted to hospital in
France, including discharge diagnoses encoded according ICD-10, medical procedures and
French diagnosis-related groups The research proposed is expected to provide an update
and nationally-consolidated estimation of the cardiovascular risk is associated to
triptans use in elderly population.
n/a
Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
| Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
| Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
| Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
| Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
| Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
| Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
| Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
| Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
| Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
| Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
| Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
| Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
| Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
| Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
| Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
| Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
| Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
| Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
| Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |